




miFuc™ Platform for Antibodies with Increased ADCC activity

Enabled by Leap-In Transposase



Functional in any cell line

Embedded in expression vector



Reduction in core fucose within any cell line


- Features:**
- Host cell agnostic, can use any host cell line
 - Enabled by Leap-In Transposase based integration
 - Mechanism delivered within expression vector
 - Stable phenotype once pools and clones are selected



Benefits:

- Extremely flexible platform:
 - Compatible with various host cell lines
 - Works across multiple vector configurations
- Significant reduction in fucosylated mAbs without global glycan liabilities

Enhanced ADCC activity



Uniquely enabling bulk pools:

- Significantly increased CD16 based signaling (ADCC)
- Robust and reproducible activity

References:

Rajendran et.al., *Biotechnol. Bioeng.*, 2021, 118(6):2301-2311

10 IND clearances as of Nov 2021 (1 in China, 7 in U.S., 2 in Europe)

Protected by more than 10 issued patents

Contact us to purchase the Leap-In Transposase® and miFuc™ platforms:

+1 650 853 8347


+1 877 DNA TOGO

info@atum.bio



+1 877 DNA TOGO
+1 650 853 8347
info@atum.bio

37950 Central Court
Newark, CA 94560



research. create. break through.

